ExplainedSaaS/ 27 May 2026/ 2 min read
MEDDIC works on outbound deals because the AE has done the upstream qualification work. It works less well on inbound because the AE inherits a lead with no upstream context. Three places inbound-MEDDIC fails predictably: champion identification, critical event surfacing, and decision process discovery.
MEDDIC works on outbound deals because the AE has done the upstream qualification work as part of the prospecting motion. It works less well on inbound because the AE inherits a lead with no upstream context and is expected to compress qualification into the first call.
Three places inbound-MEDDIC fails predictably.
On outbound, the AE built the relationship with the champion deliberately. On inbound, the lead might be the champion, might be a researcher, might be someone in a parallel team with no decision power. The MEDDIC frame says 'identify the champion', but the inbound first-meeting cannot reliably distinguish between 'this person is my champion' and 'this person looked at my pricing page and filled out a form'.
The fix is to use the first meeting to test for champion behaviour rather than to assume it. Champion behaviour: the lead can name the buying-centre stakeholders unprompted; the lead has discussed this with at least one other person internally; the lead can articulate why the company would care, not just why they personally would. Without those three signals the lead is not yet the champion.
On outbound, the AE often discovers the critical event during prospecting (the existing contract is up, a renewal trigger, a regulatory deadline). On inbound, the critical event is rarely surfaced cheaply; the lead came to you and may not have a date.
The AE running inbound-MEDDIC should make critical-event surfacing the explicit goal of the first meeting. 'What's making you look now rather than three months ago' is the question. If the lead cannot answer it, the deal does not have a critical event yet, and the forecast belongs in long-term pipeline.
This is the gap that bites hardest. Inbound leads frequently haven't thought about the decision process - they've thought about the problem. The AE assumes a process exists ('there must be a procurement step') and gets surprised at week 8 when none of it is in motion.
The fix: bring up decision process explicitly in the first meeting, not in week 6. The phrasing that works on inbound: 'When you've evaluated tools like this before, what does the approval path normally look like at your company?' This is conversational, not interrogative, and the answer reveals whether the lead has thought about it (good signal) or not (red flag).
Inbound-MEDDIC works when the AE explicitly compresses the discovery into the first meeting and explicitly tests for the three weakest dimensions: champion behaviour, critical event, decision process. AEs who run inbound deals on outbound-MEDDIC pacing routinely lose 90 days at the back of the cycle.
Snapshot
UK B2B outbound channel mix has shifted materially from 2022 to 2026: LinkedIn first, phone returning, cold email lower-volume but more personalised, direct mail seeing a small revival in enterprise. The relative effectiveness ranks have inverted from the 2022 hierarchy.
Explained
Account-based sales (ABS) was promoted heavily across UK SaaS through 2018-2023 as a structural answer to broad-volume outbound. By 2026 the picture is more nuanced: ABS works at specific deal sizes and team scales, fails predictably outside those, and many UK mid-market teams adopted it for the wrong reasons. A practitioner walkthrough.
Explained
UK enterprise buyers in 2026 increasingly run ESG due diligence on vendors as part of procurement: documented sustainability commitments, modern-slavery statement, supply-chain transparency, and (depending on the buyer) climate-disclosure alignment. The UK Sustainability Disclosure Standards regime has tightened the buyer-side disclosure obligations, which cascades down to vendor expectations.